These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 23242598)

  • 1. Darbepoietin-alfa has comparable erythropoietic stimulatory effects to recombinant erythropoietin whilst preserving the bone marrow microenvironment.
    Dewamitta SR; Russell MR; Nandurkar H; Walkley CR
    Haematologica; 2013 May; 98(5):686-90. PubMed ID: 23242598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietin couples erythropoiesis, B-lymphopoiesis, and bone homeostasis within the bone marrow microenvironment.
    Singbrant S; Russell MR; Jovic T; Liddicoat B; Izon DJ; Purton LE; Sims NA; Martin TJ; Sankaran VG; Walkley CR
    Blood; 2011 May; 117(21):5631-42. PubMed ID: 21421837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools.
    Sathyanarayana P; Houde E; Marshall D; Volk A; Makropoulos D; Emerson C; Pradeep A; Bugelski PJ; Wojchowski DM
    Blood; 2009 May; 113(20):4955-62. PubMed ID: 19264917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effectiveness of darbepoietin alfa in anemic patients with chronic kidney disease (CKD) in predialysis period].
    Wanic-Kossowska M; Tykarski A; Kobelski M; Czekalski S
    Pol Arch Med Wewn; 2006 Jul; 116(1):663-70. PubMed ID: 17340973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.
    Brophy GM; Sheehan V; Shapiro MJ; Lottenberg L; Scarlata D; Audhya P;
    Clin Ther; 2008 Dec; 30(12):2324-34. PubMed ID: 19167591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoietic recovery during treatment with darbepoietin-alpha after impaired rHuEPO response to anemia in two patients with osteomyelofibrosis after peripheral blood stem cell transplantation.
    Nguyen VA; Fauser AA; Basara N; Kiehl M
    Hematol J; 2003; 4(6):456-8. PubMed ID: 14671623
    [No Abstract]   [Full Text] [Related]  

  • 7. Optimizing the use of erythropoietic agents-- pharmacokinetic and pharmacodynamic considerations.
    Macdougall IC
    Nephrol Dial Transplant; 2002; 17 Suppl 5():66-70. PubMed ID: 12091611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immediate pain sensation is less with subcutaneous epoietin-beta compared to subcutaneous darbepoietin-alpha.
    Ter Wee PM; de Koter Y; van der Veer O; van Vliet MH
    Clin Nephrol; 2009 Sep; 72(3):177-80. PubMed ID: 19761721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
    Forbes CA; Worthy G; Harker J; Kleijnen J; Kutikova L; Zelek L; Van Belle S
    Clin Ther; 2014 Apr; 36(4):594-610. PubMed ID: 24656152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Darbepoetin alfa: a novel erythropoiesis-stimulating protein.
    Cases A
    Drugs Today (Barc); 2003 Jul; 39(7):477-95. PubMed ID: 12973399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applications of darbepoietin-alpha, a novel erythropoiesis-stimulating protein, in oncology.
    Smith R
    Curr Opin Hematol; 2002 May; 9(3):228-33. PubMed ID: 11953669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis.
    Moyo V; Lefebvre P; Duh MS; Yektashenas B; Mundle S
    Ann Hematol; 2008 Jul; 87(7):527-36. PubMed ID: 18351340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies.
    Scott SD
    Pharmacotherapy; 2002 Sep; 22(9 Pt 2):160S-165S. PubMed ID: 12222586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Erythropoiesis Stimulating Agents in the Treatment of Anemia: a Literature Review.
    Kidanewold A; Woldu B; Enawgaw B
    Clin Lab; 2021 Apr; 67(4):. PubMed ID: 33865269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics, pharmacokinetics, and tolerability of intravenous or subcutaneous GC1113, a novel erythropoiesis-stimulating agent.
    Han H; Lee J; Shin D; Shin KH; Jeon H; Lim KS; Yoon SH; Shin SG; Jang IJ; Cho JY; Yu KS
    Clin Drug Investig; 2014 Jun; 34(6):373-82. PubMed ID: 24623104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An overview of the pharmacokinetic disposition of darbepoetin alfa.
    Zamboni WC; Stewart CE
    Pharmacotherapy; 2002 Sep; 22(9 Pt 2):133S-140S. PubMed ID: 12222583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of epoetin alfa and darbepoetin alfa biological activity under different administration schedules in normal mice.
    Sasu BJ; Hartley C; Schultz H; McElroy P; Khaja R; Elliott S; Egrie JC; Browne JK; Begley CG; Molineux G
    Acta Haematol; 2005; 113(3):163-74. PubMed ID: 15870486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of cancer-related anemia: focus on the potential role of darbepoetin alfa.
    Valley AW
    Pharmacotherapy; 2002 Sep; 22(9 Pt 2):150S-159S. PubMed ID: 12222585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease.
    Horowitz J; Agarwal A; Huang F; Gitlin M; Gandra SR; Cangialose CB
    J Manag Care Pharm; 2009; 15(9):741-50. PubMed ID: 19954265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoietin-induced erythroid precursor pool depletion causes erythropoietin hyporesponsiveness.
    Yan X; Ait-Oudhia S; Krzyzanski W
    Pharm Res; 2013 Apr; 30(4):1026-36. PubMed ID: 23187865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.